Alaunos Therapeutics

Company snapshot

Alaunos is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. With our robust and innovative discovery engine, we strike cancer at its core by engineering cell therapies that target neoantigens arising from genomic mutations. We have developed proprietary, rapid, cost-effective solutions to deliver tumor-specific killer

• 34 active pipeline program(s) linked via ClinicalTrials.gov.
• 34 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Alaunos Therapeutics. Not investment advice.

• Peer + 0 momentum

  Pyxis Oncology

  TA overlap score 41.6

• Peer + 0 momentum

  Chongqing Precision Biotech

  TA overlap score 40

• Peer + 0 momentum

  Anaxis Pharma

  TA overlap score 40

• Peer + 0 momentum

  Disc Medicine

  TA overlap score 40

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 38

• Peer + 0 momentum

  Karyopharm Therapeutics

  TA overlap score 36.4

• Peer + 0 momentum

  Telix Innovations

  TA overlap score 35.4

• Peer + 0 momentum

  Cellectar Biosciences

  TA overlap score 33.4

• Peer + 0 momentum

  Nektar Therapeutics UK

  TA overlap score 31.4

• Peer + 0 momentum

  Arcus Biosciences

  TA overlap score 30.6

Recent activity

Latest pipeline, patent, and corporate events for Alaunos Therapeutics.

1. Jun 8, 2026 Clinical update

   Palifosfamide Tris and Doxorubicin — Phase 2

2. Jun 8, 2026 Clinical update

   palifosfamide — Phase 2

3. Jun 8, 2026 Clinical update

   oral palifosfamide tris — Phase 1

4. Jun 8, 2026 Clinical update

   doxorubicin in combination with palifosfamide-tris — Phase 3

5. Jun 8, 2026 Clinical update

   Darinaparsin — Phase 2

View all clinical trial activity →

• What is Alaunos Therapeutics?

  Alaunos Therapeutics is a pharma organization headquartered in Houston, USA. It trades on NYSE under ticker TCRT. Primary therapeutic focus areas include Advanced Cancer, Advanced Solid Tumors, Solid Tumors, Melanoma, Metastatic Breast Cancer. NovaPharmaNews links 34 clinical pro

• Is Alaunos Therapeutics publicly traded?

  Yes. Alaunos Therapeutics is listed with ticker TCRT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Alaunos Therapeutics develop or market?

  We link 12 drug profile(s) where Alaunos Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/alaunos-therapeutics#company-drugs.

• What are the latest developments for Alaunos Therapeutics?

  In the last 12 months our linked public records show 34 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Alaunos Therapeutics focus on?

  Alaunos Therapeutics focuses on Advanced Cancer, Advanced Solid Tumors, Solid Tumors based on our analysis of their pipeline programs and drug development activities.